ROP, BioStructures in bone remodeling products license agreement
As per the agreement, ROP has received initial $100K licensing fee from BioStructures and will also receive an additional license fees as well as royalties on sales throughout
US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity.